OPKO terminates Phase III trial of macular degeneration candidate
This article was originally published in Scrip
OPKO Health has terminated a Phase III clinical study of its only clinical product, bevasiranib, a siRNA for the treatment of wet age-related macular degeneration (wet-AMD); following a recommendation from the independent data monitoring committee which determined that the trial was unlikely to meet its primary endpoint.
You may also be interested in...
Emerging Company Profile: Alnylam's success with late-stage patisiran raised expectations for other RNAi firms, like South Korea's OliX Pharmaceuticals. OliX is developing locally administered treatments for dermal, ophthalmic and pulmonary indications in hopes of cementing its leadership in Asia and beyond.
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.